Successful NIHR grant Philip Fowler, 29th June 20185th August 2018 Last year I coordinated a bid to the NIHR for capital to improve our research capacity to study antimicrobial resistance (AMR) at the Oxford Biomedical Research Centre. We were successful and were awarded £1.8 million to fund several different activities, including developing vaccines to prevent the spread of AMR. Previously in the John Radcliffe hospital Clinical Microbiology had one small second-generation genetic sequencer; now as a result of the grant we have a second, but more crucially, two very high-throughput third-generation genetic sequencers. These are GridIONs from Oxford Nanopore and sequence DNA in a completely different way that could revolutionise the use of genetics in Clinical Microbiology. Grants like this all too-often often focus on the experimental equipment at the expense of the compute and storage you need to analyse and store the data. We were fortunate to secure funds to provide a small processing cluster in the room next to the sequencing facility in addition to much larger storage and compute at the Big Data Institute, part of which my group will be able to use to continue to develop methods for de novo prediction of the effect of individual protein mutations on the actions of antibiotics. Share this:Twitter Related antimicrobial resistance clinical microbiology grants research
antimicrobial resistance AMyGDA now available from GitHub 27th January 202027th January 2020 AMyGDA is a python module that analyses photographs of 96-well plates and, by examining each… Share this:Twitter Read More
antimicrobial resistance New publication: Phylogenetically informative mutations in genes implicated in antibiotic resistance in Mycobacterium tuberculosis complex 9th March 202016th March 2020 Although the population structure M. tuberculosis is clonal, one must be careful when inferring the… Share this:Twitter Read More
This blog… 31st October 2012 …is where I shall put thoughts that at least might be of interest to other… Share this:Twitter Read More